Histogenics Corp., of Waltham, Mass., said it closed its underwritten public offering of 26.15 million shares and warrants to purchase up to 19.61 million shares at a combined purchase price of 65 cents per share and accompanying warrant. The net proceeds are approximately $15.4 million.